COVID-19：メディカゴ社VLPワクチン第1相試験結果：MT-2766（動画）：
COVID-19: Medicago VLP Vaccine Phase 1 Test Results: MT-2766：
COVID-19：Medicago VLP疫苗第1阶段测试结果：MT-2766
―VLPワクチン第1相臨床試験結果を発表―
田辺三菱製薬：
メディカゴ社：カナダ ケベック・連結子会社
メディカゴ社が、現在開発中のVLPワクチンで、COVID-19予防をめざしています。
植物由来のウイルス様粒子（VLP*）ワクチン（開発番号：MT-2766）の第１相臨床試験を、実施しました。
「良好な結果が得られたことを発表しました」ので、お知らせします。
本第１相臨床試験及び結果の概要は、以下の通りです。
田辺三菱製薬
https://www.mt-pharma.co.jp/news/2020/MTPC201111.html
Initiatives Against COVID-19 in Canada
– Phase 1 Results for COVID-19 Vaccine Candidate
November 11, 2020
Mitsubishi Tanabe Pharma Corporation
announced today that
its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; CEO; Bruce D. Clark)
has announced the positive results of the Phase 1 clinical trial of its plant-derived virus-like particle (VLP) vaccine (project code:MT-2766) for the prevention of coronavirus disease 2019 (COVID-19) which has being developed by Medicago.
The summary of the Phase 1 clinical study and results are as follows:
■Subjects: 180 healthy Canadian subjects, male and female aged 18-55.
■Dosage and administration: Evaluated dosages of 3.75, 7.5 or 15 μg of the VLP vaccine candidate alone or with each of the two adjuvants – GSK’s adjuvant and Dynavax’s adjuvant after two doses.
■Endpoints: Safety and immunogenicity.
■Results: Induced robust neutralizing antibody and cellular immune response in the adjuvant group.
No severe adverse events were observed.
Based on the overall data profile,
Medicago plans to proceed with the Phase 2/3 clinical trial, subject to regulatory approval.
Mitsubishi Tanabe Pharma Group will work to develop and deliver MT-2766 to society as soon as possible, contributing even further to the prevention of COVID- 19, a pressing social issue.
Medicago release (November 10, 2020, local time) Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate.
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC201111.pdf
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
QUEBEC CITY, November 10th, 2020 – Medicago, a biopharmaceutical company headquartered in Quebec City,
is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19.
The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.